These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 8382865

  • 1. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S, Mayo C, McCullough C, Jendrisak M, Woodle S, Marsh W, Bailey T.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract] [Full Text] [Related]

  • 2. Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients.
    Prokurat S, Drabik E, Grenda R, Vogt E.
    Transplant Proc; 1993 Aug; 25(4):2577. PubMed ID: 8395104
    [No Abstract] [Full Text] [Related]

  • 3. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ, van den Berg AP, The TH, Tegzess AM.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract] [Full Text] [Related]

  • 4. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients.
    Buturović-Ponikvar J, Kandus A, Malovrh M, Ponikvar R, Kveder R.
    Transplant Proc; 1992 Oct; 24(5):1921-3. PubMed ID: 1329287
    [No Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus prophylaxis in antibody-treated renal transplanted patients.
    Birkeland S, Gahrn-Hansen B, Andersen H, Rohr N, Larsen KE, Jørgensen A.
    Transplant Proc; 1995 Dec; 27(6):3473-6. PubMed ID: 8540056
    [No Abstract] [Full Text] [Related]

  • 6. Incidence of cytomegalovirus infection in kidney recipients.
    Bilgin N, Karakayali H, Moray G, Akkoç H, Turan M.
    Transplant Proc; 1996 Aug; 28(4):2314-5. PubMed ID: 8769233
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Aug; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C, Ducloux D, Ferroni A, Chkoff N, Valette C, Geffrier C, Rouzioux C, Kreis H.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871
    [No Abstract] [Full Text] [Related]

  • 11. CMV in kidney transplantation: a single center experience over 22 years.
    Nashan B, Lück R, Kliem V, Brunkhorst R, Schlitt HJ, Klempnauer J.
    Clin Transpl; 1999 Feb; ():181-8. PubMed ID: 11038636
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
    Dickenmann MJ, Kabulbayev K, Steiger J, Cathomas G, Reusser P, Tamm M.
    Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
    [Abstract] [Full Text] [Related]

  • 14. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M, Velidedoğlu E, Arslan G, Bilgin N, Büyükpamukçu N, Karamehmetoğlu M.
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract] [Full Text] [Related]

  • 15. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Oct; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 16. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
    Klauser R, Zlabinger GJ, Traindl O, Franz M, Watschinger B, Pohanka E, Kudlacek S, Kovarik J.
    Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK, Kim YS, Kim MS, Kim SI, Park K.
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract] [Full Text] [Related]

  • 18. Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation.
    Delone P, Corkill J, Jordan M, Krapiva P, Ghasemian R, Sasaki T, Light JA.
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):58-9. PubMed ID: 7482823
    [No Abstract] [Full Text] [Related]

  • 19. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
    Fukuuchi F, Lefrançois N, Chapuis F, Gebuhrer L, Bosshard S, Dubernard JM, Touraine JL.
    Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
    [No Abstract] [Full Text] [Related]

  • 20. Ganciclovir prophylaxis of cytomegalovirus disease.
    Conti DJ, Shen G, Singh T, Isenberg A, Freed BM.
    Transplant Proc; 1997 Oct; 29(1-2):804-6. PubMed ID: 9123534
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.